Forced Labour in Supply Chains

Canada, as many other countries, has taken serious steps to address and eradicate from its supply chains exploitative practices such as forced labour and child labour.

Mantra Pharma Inc. (“Mantra Pharma”) is committed to respect the human rights and adopt a zero-tolerance approach to forced labour and child labour and act ethically in all its business relationships.

To pursue this objective, Mantra Pharma aims to increase its awareness and transparency to improve its general practices. Therefore, any future amendment, renewal, or new agreement with Mantra Pharma shall introduce anti-forced labour and anti-child labour contractual compliance clauses. Any third-party supplier shall and shall ensure that each of its subcontractors shall comply with all applicable forced labour or child labour laws, statutes, regulations in force in Canada and any other jurisdictions where it operates, including but not limited to, Fighting Against Forced Labour and Child Labour in Supply Chains Act.

Mantra Pharma expect its suppliers to take all reasonable steps to ensure that there is no forced labour or child labour in any supplier’s or subcontractors’ supply chains or in any part of its or their business. Mantra Pharma shall now require from any of its suppliers to confirm that neither it, nor any of its officers, employees or other persons associated with it has been convicted of any offence involving forced labour or child labour or has been or is the subject of any investigation regarding any offence or alleged offence in connection with forced labour or child labour.

Mantra Pharma asks the collaboration of every member of its supply chain to immediately inform Mantra Pharma of any actual or suspected forced labour or child labour in any supply chain in connection with an agreement with Mantra Pharma. Mantra Pharma will react accordingly to any identified transgression by its suppliers and continue to monitor and evaluate its approach to prevent forced labour and child labour. For more information, read the annual report.

Mantra Pharma appreciates your collaboration to bring this approach to fruition, which must be a global collective will.

Jean-François Letarte, President